Erratum: C/EBPα Induces Highly Efficient Macrophage Transdifferentiation of B Lymphoma and Leukemia Cell Lines and Impairs Their Tumorigenicity (Cell Reports (2013) 3(4) (1153–1163) (S2211124713001101) (10.1016/j.celrep.2013.03.003));C/EBPα Induces Highly Efficient Macrophage Transdifferentiation of B Lymphoma and Leukemia Cell Lines and Impairs Their Tumorigenicity

Cell Reports

Volumn 3, Issue 4, 2013, Pages 1153-1163

  Rapino, Francesca ^a   Robles, Eloy F ^b   Richter Larrea, Jose A ^b   Kallin, Eric M ^a   Martinez Climent, Jose A ^b   Graf, Thomas ^a  

^a CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; DOXYCYCLINE; ESTROGEN RECEPTOR; TAMOXIFEN; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CARCINOGENICITY; CELL CLONE; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHATIC LEUKEMIA; LYMPHOMA CELL LINE; MACROPHAGE; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; NUCLEOTIDE SEQUENCE; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION;

MURINAE;

EID: 84876954331     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2017.04.072     Document Type: Erratum

References (28)

1. Bussmann L.H., Schubert A., Vu Manh T.P., De Andres L., Desbordes S.C., Parra M., Zimmermann T., Rapino F., Rodriguez-Ubreva J., Ballestar E., Graf T. A robust and highly efficient immune cell reprogramming system. Cell Stem Cell 2009, 5:554-566.
2. Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., Jaffe E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117:5019-5032.
3. Cerchietti L.C., Ghetu A.F., Zhu X., Da Silva G.F., Zhong S., Matthews M., Bunting K.L., Polo J.M., Farès C., Arrowsmith C.H., et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010, 17:400-411.
4. Chao M.P., Alizadeh A.A., Tang C., Myklebust J.H., Varghese B., Gill S., Jan M., Cha A.C., Chan C.K., Tan B.T., et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010, 142:699-713.
5. Di Tullio A., Graf T. C/EBPα bypasses cell cycle-dependency during immune cell transdifferentiation. Cell Cycle 2012, 11:2739-2746.
6. Drexler H.G. Guide to Leukemia-Lymphoma Cell Lines 2005, DSMZ, Brunswick, Germany. http://www.dsmz.de/research/human-and-animal-cell-lines/guide-to-leukemia-lymphoma-cell-lines.html.
7. Graf T., Enver T. Forcing cells to change lineages. Nature 2009, 462:587-594.
8. Hochedlinger K., Blelloch R., Brennan C., Yamada Y., Kim M., Chin L., Jaenisch R. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 2004, 18:1875-1885.
9. Jack I., Seshadri R., Garson M., Michael P., Callen D., Zola H., Morley A. RCH-ACV: a lymphoblastic leukemia cell line with chromosome translocation 1;19 and trisomy 8. Cancer Genet. Cytogenet. 1986, 19:261-269.
10. Keppler-Ross S., Noffz C., Dean N. A new purple fluorescent color marker for genetic studies in Saccharomyces cerevisiae and Candida albicans. Genetics 2008, 179:705-710.
11. Koschmieder S., Halmos B., Levantini E., Tenen D.G. Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J. Clin. Oncol. 2009, 27:619-628.
12. Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R., Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marín M., et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007, 109:271-280.
13. Nowak D., Stewart D., Koeffler H.P. Differentiation therapy of leukemia: 3 decades of development. Blood 2009, 113:3655-3665.
14. Oricchio E., Nanjangud G., Wolfe A.L., Schatz J.H., Mavrakis K.J., Jiang M., Liu X., Bruno J., Heguy A., Olshen A.B., et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 2011, 147:554-564.
15. Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S., Schnittger S., Behre G., Hiddemann W., Tenen D.G. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat. Genet. 2001, 27:263-270.
16. Richter-Larrea J.A., Robles E.F., Fresquet V., Beltran E., Rullan A.J., Agirre X., Calasanz M.J., Panizo C., Richter J.A., Hernandez J.M., et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 2010, 116:2531-2542.
17. Ritchie M.E., Silver J., Oshlack A., Holmes M., Diyagama D., Holloway A., Smyth G.K. A comparison of background correction methods for two-colour microarrays. Bioinformatics 2007, 23:2700-2707.
18. Sachlos E., Risueño R.M., Laronde S., Shapovalova Z., Lee J.H., Russell J., Malig M., McNicol J.D., Fiebig-Comyn A., Graham M., et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012, 149:1284-1297.
19. Schepers H., Wierenga A.T., van Gosliga D., Eggen B.J., Vellenga E., Schuringa J.J. Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood 2007, 110:1317-1325.
20. Shaffer A.L., Young R.M., Staudt L.M. Pathogenesis of human B cell lymphomas. Annu. Rev. Immunol. 2012, 30:565-610.
21. Stadtfeld M., Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev. 2010, 24:2239-2263.
22. Stadtfeld M., Maherali N., Breault D.T., Hochedlinger K. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell 2008, 2:230-240.
23. Toujani S., Dessen P., Ithzar N., Danglot G., Richon C., Vassetzky Y., Robert T., Lazar V., Bosq J., Da Costa L., et al. High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma. PLoS One 2009, 4:e7089.
24. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J.C., Lanzavecchia A., Manz M.G. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004, 304:104-107.
25. Valk P.J., Verhaak R.G., Beijen M.A., Erpelinck C.A., Barjesteh van Waalwijk van Doorn-Khosrovani S., Boer J.M., Beverloo H.B., Moorhouse M.J., van der Spek P.J., Löwenberg B., Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 2004, 350:1617-1628.
26. Waxman S. Differentiation therapy in acute myelogenous leukemia (non-APL). Leukemia 2000, 14:491-496.
27. Xie H., Ye M., Feng R., Graf T. Stepwise reprogramming of B cells into macrophages. Cell 2004, 117:663-676.
28. Zhang P., Iwasaki-Arai J., Iwasaki H., Fenyus M.L., Dayaram T., Owens B.M., Shigematsu H., Levantini E., Huettner C.S., Lekstrom-Himes J.A., et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity 2004, 21:853-863.